(19)
(11) EP 4 771 001 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24786348.3

(22) Date of filing: 30.08.2024
(51) International Patent Classification (IPC): 
C07D 401/14(2006.01)
C07D 405/14(2006.01)
A61K 31/4245(2006.01)
A61K 31/4709(2006.01)
A61K 31/497(2006.01)
A61P 9/10(2006.01)
A61P 13/12(2006.01)
C07D 403/14(2006.01)
C07D 413/14(2006.01)
A61K 31/4439(2006.01)
A61K 31/4965(2006.01)
A61P 3/10(2006.01)
A61P 11/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 413/14; C07D 403/14; C07D 405/14; C07D 401/14; A61P 3/10; A61P 13/12; A61P 11/00; A61P 9/10; A61K 45/06
(86) International application number:
PCT/CN2024/115894
(87) International publication number:
WO 2025/045208 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 31.08.2023 WO PCT/CN2023/116141

(71) Applicant: Gasherbrum Bio, Inc.
South San Francisco, CA 94080 (US)

(72) Inventors:
  • HUANG, Wei
    Shanghai 200003 (CN)
  • LEI, Hui
    Shanghai 200003 (CN)
  • LU, Chunliang
    Shanghai 200003 (CN)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) HETEROARYL-HETEROCYCLOALKYL-BASED GLP-1 AGONISTS